Induced Pluripotent Stem Cell-Derived Cardiomyocytes: From Regulatory Status to Clinical Translation

Area of Science:

• Cardiovascular medicine
• Regenerative medicine
• Stem cell biology

Background:

• Cardiovascular diseases are a leading global cause of death, with limited regenerative therapies.
• Stem cell therapies, particularly induced pluripotent stem cells (iPSPs), offer potential for cardiomyocyte regeneration.
• Current large-scale iPSC production lacks standardized Good Manufacturing Practice (GMP) guidelines, posing quality risks.

Purpose of the Study:

• To identify critical quality attributes (CQAs) for iPSC-derived cardiomyocytes (iPSC-CMs).
• To ensure regulatory compliance and patient safety in cardiovascular therapy development.
• To review existing legislation and regulatory guidelines from EMA, FDA, and PMDA.

Main Methods:

• Literature review of iPSCs and iPSC-CM therapies.
• Analysis of regulatory guidelines from major health agencies (EMA, FDA, PMDA).
• Identification of key quality attributes and regulatory gaps.

Main Results:

• Lack of standardized GMP for large-scale iPSC production.
• Potential quality risks in iPSC products may compromise patient safety.
• Need for enhanced regulations for iPSC-CM differentiation, maturation, and tumorigenicity monitoring.

Conclusions:

• Additional regulations and guidelines are essential for monitoring iPSC-CM development.
• GMP-compliant cell banks and fast-track approval systems could improve patient access.
• Standardized CQAs are crucial for safe and effective iPSC-CM cardiovascular therapies.